Catalyst Pharma Closes Previously Announced $6 Million Registered Direct Offering

Catalyst PharmaceuticalPartners (Nasdaq: CPRX) announced today that it has closed its previouslyannounced offering of (i) 4.0 million shares of the Company's common stock,and (ii) warrants to purchase an aggregate of 1.2 million shares of theCompany's common stock, in a registered direct public offering. The aggregateoffering price for each share and corresponding warrant was $1.50, resultingin gross proceeds of $6 million. The common stock purchase warrants have afive-year term and an exercise price of $2.08 per share. Roth Capital Partnersacted as the exclusive placement agent for the transaction."We are pleased to have completed this financing, which gives us additionalresources to further our product development efforts," said Patrick J.McEnany, the Company's Chairman and Chief Executive Officer. "Earlier thisyear, we sought to raise approximately $10 million in financing to support ourbusiness activities. However, at the time, due primarily to adverse marketconditions, we were only able to raise about $4.8 million. This new offeringmakes up for that shortfall and is on better terms than we were able to obtainin our earlier financing."